Bisoprolol / Cilnidipine / Telmisartan (Ravenbhel Healthcare)

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameBisoprolol / Cilnidipine / Telmisartan (Ravenbhel Healthcare)
Drug Alias Namebisoprolol + cilnidipine + telmisartan
ClassificationSmall molecules
Mechanisms of ActionN-Type Calcium channels inhibitorsAngiotensin II receptor antagonistsBeta-1 adrenergic receptor degraders +[4] 
TargetsAngiotensin II receptorVoltage-gated L-type calcium channelBeta-1 adrenergic receptor +[4] 
Therapy Area/IndicationsHypertensionCoronary Artery Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIndia
CombinationsYes
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRavenbhel Healthcare Pvt Ltd
China Registration ClassN/A

Develop Information

Active CompaniesRavenbhel Healthcare Pvt Ltd
Inactive CompaniesN/A
Active IndicationsHypertensionCoronary Artery Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A